The US Prostate Cancer Business is one of the largest and fastest growing businesses within Pfizer. It is anchored by a multibillion-dollar asset in XTANDI, as well as the more recently launched products in ORGOVYX and Talzenna (talazoparib) in metastatic castration resistant prostate cancer (mCRPC). TALZENNA in prostate is one of Pfizer Oncology’s 10 priority brands. It has the potential to deliver over $1B in peak revenues globally and contribute meaningfully to our growing Prostate portfolio. Having launched the first indication in metastatic castration-resistant prostate cancer (mCRPC) (TALAPRO-2) in June 2023, we are growing Talzenna’s market presence in HRR-mutated mCRPC, as well as preparing for a potential future indication in HRR-mutated metastatic castration-sensitive prostate cancer (mCSPC) (TALAPRO-3). The US TALZENNA HCP Lead and Launch Lead will join a highly talented marketing team to drive launch success for Talzenna, and is accountable for: Overall TALZENNA prostate HCP marketing strategies and plan, including prioritization of resources to maximize the commercial potential of the brand.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Bachelor's degree
Number of Employees
5,001-10,000 employees